Epigenomics makes Thomas Taapken CFO
This article was originally published in Clinica
Thomas Taapken will become the CFO of German molecular diagnostics firm Epigenomics on 1 April 2011. Dr Taapken will join Berlin-based Epigenomics from Biotie Therapies, a Finnish drug development firm, where he holds the same position. He has previously worked for Sanofi-Aventis in the US and Germany, and for San Francisco-based venture capital firm Burrill & Company, among other firms. Dr Taapken will replace outgoing CFO Oliver Schacht, who is leaving to become the CEO of Curetis, a molecular diagnostics specialist based in Holzgerlingen, Germany. Epigenomics said that it is looking to recruit a marketing and sales executive to head its US-based operations, which are currently run by Mr Schacht.